ReviewBioMed research international2025
Novel Strategies to Profile SARS-CoV-2 and Human Lung Proteome: Inflammatory Pathways in the Spotlight.
Review in BioMed research international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Novel Strategies to Profile SARS-CoV-2 and Human Lung Proteome: Inflammatory Pathways in the Spotlight.BioMed research international · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, has caused widespread morbidity and mortality worldwide. SARS-CoV-2 infection triggers innate and adaptive immune responses, but excessive cytokine release can drive hyperinflammation, acute respiratory distress syndrome and poor clinical outcomes. Although serological and molecular assays, such as ELISA and RT-qPCR, remain central to COVID-19 diagnostics, they have limited capacity to reveal host-pathogen interactions at the tissue level. Therefore, profiling the human lung proteome offers a powerful strategy to identify molecular signatures associated with viral pathogenesis and disease severity. This review emphasises emerging technologies that advance lung proteome profiling during SARS-CoV-2 infection. Novel strategies include phage display for high-throughput identification of antibody-antigen interactions, yeast two-hybrid for mapping virus-host protein interactions and lateral flow immunoassays for rapid, point-of-care detection. Conversely, omics-based technologies such as single-cell RNA sequencing, microarrays and mass spectrometry are transforming our understanding of the lung proteome by revealing patterns of gene expression, protein abundance and immune heterogeneity. Therefore, comparing these conventional diagnostic assays with innovative approaches, we highlight their unique contributions to lung proteome research. These tools not only improve diagnostic precision but also hold the potential to uncover biomarkers for early risk stratification and therapeutic targeting. Prioritising integrative proteome-focused strategies may ultimately guide personalised interventions and enhance preparedness for future viral outbreaks.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.